Last reviewed · How we verify
Perioperative Corticosteroids
Corticosteroids suppress the inflammatory and immune response by binding to glucocorticoid receptors, reducing the production of pro-inflammatory cytokines and mediators.
Corticosteroids suppress the inflammatory and immune response by binding to glucocorticoid receptors, reducing the production of pro-inflammatory cytokines and mediators. Used for Perioperative anti-inflammatory prophylaxis in major surgery, Prevention of postoperative complications including systemic inflammatory response and organ dysfunction.
At a glance
| Generic name | Perioperative Corticosteroids |
|---|---|
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Surgery/Perioperative Medicine |
| Phase | FDA-approved |
Mechanism of action
Perioperative corticosteroids are administered around the time of surgery to dampen the acute inflammatory response triggered by surgical trauma and anesthesia. By activating intracellular glucocorticoid receptors, they inhibit nuclear factor-kappa B (NF-κB) signaling and reduce expression of inflammatory genes, thereby decreasing cytokine release, edema, and immune activation. This can reduce postoperative complications such as systemic inflammatory response syndrome, infection risk, and organ dysfunction.
Approved indications
- Perioperative anti-inflammatory prophylaxis in major surgery
- Prevention of postoperative complications including systemic inflammatory response and organ dysfunction
Common side effects
- Hyperglycemia
- Immunosuppression/increased infection risk
- Hypertension
- Insomnia
- Mood changes
Key clinical trials
- Efficacy and Safety of Methylprednisolone After Flow-Diverter Stent Implantation in Unruptured Intracranial Aneurysms (PHASE4)
- Effect of IV Dexamethasone on Post-op Urinary Retention After Spinal Anesthesia (NA)
- Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA) (PHASE4)
- Human Albumin for Resuscitation in Surgical Septic Shock: A Randomized Controlled Trial (ALBUS Study) (PHASE3)
- Effect of Low-Level Light Therapy on Ocular Surface Parameters in Patients Undergoing Femto-Lasik Surgery (NA)
- Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery (PHASE4)
- Planned Delivery at 37 Versus 36 Weeks in Pregnancies With Placenta Previaand Accreta (NA)
- Steroid Administration for Articular Fractures of the Elbow (SAFE Trial) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: